Literature DB >> 17276524

Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells.

P Schlatter1, C Beglinger, J Drewe, H Gutmann.   

Abstract

BACKGROUND: GLP-1 is secreted into the circulation after food intake. The main biological effects of GLP-1 include stimulation of glucose dependent insulin secretion and induction of satiety feelings. Recently, it was demonstrated in rats and humans that GLP-1 can stimulate renal excretion of sodium. Based on these data, the existence of a renal GLP-1 receptor (GLP-1R) was postulated. However, the exact localization of the GLP-1R and the mechanism of this GLP-1 action have not yet been investigated.
METHODS: Primary porcine proximal tubular cells were isolated from porcine kidneys. Expression of GLP-1R was measured at the mRNA level by quantitative RT-PCR. Protein expression of GLP-1R was verified with immunocytochemistry, immunohistochemistry and Western blot analysis. Functional studies included transport assessments of sodium and glucose using three different GLP-1 concentrations (200 pM, 2 nM and 20 nM), 200 pM exendin-4 (GLP-1 analogue) and an inhibitor of the dipeptidylpeptidase IV (DPPIV) enzyme (P32/98 at 10 microM). Finally, the expression of NHE3, the predominant Na(+)/H(+) exchanger in proximal tubular cells, was also investigated.
RESULTS: GLP-1R, NHE3 and DPPIV were expressed at the mRNA level in porcine proximal tubular kidney cells. GLP-1R expression was confirmed at the protein level. Staining of human and pig kidney cortex revealed that GLP-1R was predominantly expressed in proximal tubular cells. Functional assays demonstrated an inhibition of sodium re-absorption with GLP-1 after 3 h of incubation. Exendin-4 and GLP-1 in combination with P32/98 co-administration had no clear influence on glucose and sodium uptake and transport.
CONCLUSION: GLP-1R is functionally expressed in porcine proximal tubular kidney cells. Addition of GLP-1 to these cells resulted in a reduced sodium re-absorption. GLP-1 had no effect on glucose re-absorption. We conclude that GLP-1 modulates sodium homeostasis in the kidney most likely through a direct action via its GLP-1R in proximal tubular cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17276524     DOI: 10.1016/j.regpep.2006.12.016

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  53 in total

Review 1.  GLP-1 Agonists and Blood Pressure: A Review of the Evidence.

Authors:  Aditya Goud; Jixin Zhong; Matthew Peters; Robert D Brook; Sanjay Rajagopalan
Journal:  Curr Hypertens Rep       Date:  2016-02       Impact factor: 5.369

Review 2.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

Review 3.  Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA.

Authors:  Dorrin Zarrin Khat; Mansoor Husain
Journal:  Curr Diab Rep       Date:  2018-06-09       Impact factor: 4.810

Review 4.  Renal Effects of Incretin-Based Diabetes Therapies: Pre-clinical Predictions and Clinical Trial Outcomes.

Authors:  Scott C Thomson; Volker Vallon
Journal:  Curr Diab Rep       Date:  2018-04-13       Impact factor: 4.810

5.  Gut sensing of dietary K⁺ intake increases renal K⁺excretion.

Authors:  Ki-Sook Oh; Young Taek Oh; Sang-Wook Kim; Toshihiro Kita; Insug Kang; Jang H Youn
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-05-04       Impact factor: 3.619

6.  Renal hemodynamic effects of glucagon-like peptide-1 agonist are mediated by nitric oxide but not prostaglandin.

Authors:  Scott C Thomson; Ali Kashkouli; Zhi Zhao Liu; Prabhleen Singh
Journal:  Am J Physiol Renal Physiol       Date:  2017-07-19

7.  Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection.

Authors:  Daisuke Katagiri; Yoshifumi Hamasaki; Kent Doi; Koji Okamoto; Kousuke Negishi; Masaomi Nangaku; Eisei Noiri
Journal:  J Am Soc Nephrol       Date:  2013-10-03       Impact factor: 10.121

Review 8.  Clinical therapeutic strategies for early stage of diabetic kidney disease.

Authors:  Munehiro Kitada; Keizo Kanasaki; Daisuke Koya
Journal:  World J Diabetes       Date:  2014-06-15

Review 9.  Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence.

Authors:  Radica Z Alicic; Emily J Cox; Joshua J Neumiller; Katherine R Tuttle
Journal:  Nat Rev Nephrol       Date:  2020-11-20       Impact factor: 28.314

Review 10.  The evolving place of incretin-based therapies in type 2 diabetes.

Authors:  Baptist Gallwitz
Journal:  Pediatr Nephrol       Date:  2010-02-04       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.